Horizon Blue Cross and Blue Shield of New Jersey policies, page 8

Search Horizon Blue Cross and Blue Shield of New Jersey's public medical, payment and drug policies by CPT or HCPCS code, keyword or policy number, with links to the payer's own documents. Links open the payer's own document; check its current version before relying on it.

834 public policies Substrate tracks for Horizon Blue Cross and Blue Shield of New Jersey, by title.

Horizon Blue Cross and Blue Shield of New Jersey policies
PolicyDetailsCodesSource
Hematopoietic Cell Transplantation for Miscellaneous Solid Tumors in AdultsCommercial, Medicaid—Original policy ↗
Hematopoietic Cell Transplantation for Non-Hodgkin LymphomasCommercial, Medicaid—Original policy ↗
Hematopoietic Cell Transplantation for Plasma Cell Dyscrasias, Including Multiple Myeloma and POEMS SyndromeCommercial, Medicaid1Original policy ↗
Hematopoietic Cell Transplantation for Primary AmyloidosisCommercial, Medicaid—Original policy ↗
Hematopoietic Cell Transplantation for Solid Tumors of ChildhoodCommercial, Medicaid—Original policy ↗
Hematopoietic Cell Transplantation for Waldenstrom MacroglobulinemiaCommercial, Medicaid—Original policy ↗
Hematopoietic Cell Transplantation in the Treatment of Germ Cell TumorsCommercial, Medicaid—Original policy ↗
Hematopoietic Stem Cell Transplantation for Breast CancerCommercial, Medicaid—Original policy ↗
Hemophilia Products - Congenital Factor VIII (Hemophilia A) with or without inhibitors: HemlibraCommercial—Original policy ↗
Hemophilia Products - Congenital Factor XIII Deficiency: CorifactCommercial—Original policy ↗
Hemophilia Products - Factor VIII (Hemophilia A) and Factor IX (Hemophilia B) with inhibitors, Acquired Hemophilia, Congenital Factor VII Deficiency, and Glanzmann’s Thrombasthenia: Novoseven RT and SevenfactCommercial—Original policy ↗
Hemophilia Products - Factor VIII (Hemophilia A) and Factor IX (Hemophilia B) with Inhibitors: Feiba NFCommercial—Original policy ↗
Hemophilia Products - Factor VIII (Hemophilia A) and Von Willebrand disease (VWD): Alphanate, Humate-P, and WilateCommercial—Original policy ↗
Hemophilia Products - Factor X: CoagadexCommercial—Original policy ↗
Hemophilia Products – Congenital Factor XIII A-Subunit Deficiency: TrettenCommercial—Original policy ↗
Hemophilia Products – Factor IX (Hemophilia B): Alphanine SD, Alprolix, Bebulin, Benefix, Idelvion, Ixinity, Mononine, Profilnine, Rebinyn, and RixubisCommercial—Original policy ↗
Hemophilia Products – Factor VIII (Hemophilia A, Congenital and Acquired): Advate, Adynovate, Afstyla, Eloctate, Helixate FS, Hemofil M, Koate-DVI, Kogenate FS, Kovaltry, Monoclate-P, Novoeight, NUWIQ, Recombinate, Xyntha, Obizur, Jivi and EsperoctCommercial—Original policy ↗
Hemophilia Products – von Willebrand Factor (von Willebrand Disease): VonvendiCommercial—Original policy ↗
Hip ResurfacingEffective Dec 3, 2018 · Commercial, Medicaid—Original policy ↗
HippotherapyCommercial, Medicaid1Original policy ↗
Histone Deacetylase Inhibitor(s) [Romidepsin (Istodax®)]Commercial—Original policy ↗
Home Cardiorespiratory MonitoringCommercial, Medicaid2Original policy ↗
Home Oxygen TherapyCommercial, Medicaid2Original policy ↗
Home Positive Pressure VentilationCommercial, Medicaid72Original policy ↗
Home SpirometryCommercial, Medicaid3Original policy ↗
Home Traction Devices for the Treatment of Spinal Disorders and PainCommercial, Medicaid4Original policy ↗
Homocysteine Testing in the Screening, Diagnosis, and Management of Cardiovascular Disease and Venous Thromboembolic DiseaseCommercial—Original policy ↗
Horizon BCBSNJ Reimbursement Policies & GuidelinesCommercial2Original policy ↗
Horizon Fee Schedule Updates Based on Third Party SourcesEffective Jan 1, 2022 · Commercial, Medicaid—Original policy ↗
Hospital Non-Patient Laboratory ServicesEffective Jan 1, 2021 · Commercial56Original policy ↗
Hosted Medical Policy ContentCommercial, Medicaid—Original policy ↗
Hot or Cold Pack TherapyEffective Jun 1, 2013 · Commercial, Medicaid1Original policy ↗
Human Leukocyte Antigen Testing for Celiac DiseaseEffective Aug 1, 2017 · Commercial—Original policy ↗
Hyperbaric Oxygen TherapyCommercial, Medicaid3Original policy ↗
Hyperthermia in Conjunction with Radiation TherapyCommercial—Original policy ↗
Hyperthermic Intraperitoneal Chemotherapy for Select Intra-Abdominal and Pelvic MalignanciesCommercial, Medicaid—Original policy ↗
Ibalizumab-uiyk (Trogarzo)—Original policy ↗
Identification of Microorganisms Using Nucleic Acid ProbesCommercial, Medicaid26Original policy ↗
Image-Guided Minimally Invasive Decompression for Spinal StenosisCommercial2Original policy ↗
Image-Guided Radiation Therapy (IGRT)Effective Jan 1, 2015 · Commercial, Medicaid12Original policy ↗
Imlygic (Talimogene Laherparepvec)Commercial—Original policy ↗
Immune Cell Function AssayCommercial—Original policy ↗
Immune Globulin Subcutaneous (Hizentra, Gammagard Liquid, Gamunex-C/Gammaked, HyQvia, Cuvitru, Cutaquig, and Xembify for Subcutaneous Administration)Commercial9Original policy ↗
Implantable Bone-Conduction and Bone-Anchored Hearing AidsCommercial, Medicaid—Original policy ↗
Implantable Cardioverter Defibrillator (ICD)Commercial, Medicaid1Original policy ↗
Implantable Intrathecal Drug Delivery SystemsCMM-210 · Commercial—Original policy ↗
Implantation of Intrastromal Corneal Ring SegmentsCommercial—Original policy ↗
In Vitro Chemosensitivity and Chemoresistance AssaysCommercial—Original policy ↗
In Vivo Analysis of Colorectal PolypsCommercial, Medicaid—Original policy ↗
Inebilizumab-cdon (Uplizna)Commercial—Original policy ↗

Back to Horizon Blue Cross and Blue Shield of New Jersey

Disclaimer

The information provided on this page is for general informational purposes only and does not constitute billing, coding, or reimbursement advice. Nothing on this page should be relied upon as a substitute for clinician assessment, professional billing guidance, or as a definitive statement of any payor's billing requirements or policies.

Payor agreements, fee schedules, and billing policies vary and are subject to change. Before submitting any claims related to maternity care services, including claims affected by the 2027 CPT code revisions, please consult the applicable payor agreements, coverage policies, and billing guidelines to confirm current requirements for their specific payor contracts.

Substrate makes no representation or warranty regarding the accuracy, completeness, or timeliness of the payor-specific information presented here. Providers are solely responsible for ensuring that all claims are submitted in accordance with applicable payor requirements, and Substrate assumes no liability for claim denials, underpayments, or other adverse outcomes arising from reliance on this information.